{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:44:55Z","timestamp":1791315895360,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clinthera.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:17:38Z","timestamp":1680747458000},"page":"333-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-4601","authenticated-orcid":false,"given":"T\u00edmea","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Rokszin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibolya","family":"F\u00e1bi\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"M\u00e1rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsa","family":"Bagoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Aradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"J\u00e1rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Csan\u00e1di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.03.008_bib0001","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0002","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","article-title":"Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study","volume":"44","author":"Bj\u00f6rck","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1556\/OH.2012.29305","article-title":"The prevalence of atrial fibrillation in Hungary","volume":"153","author":"Tomcs\u00e1nyi","year":"2012","journal-title":"Orv Hetil"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0006","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults. National implication for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0007","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.mayocp.2016.08.022","article-title":"The state of the art: atrial fibrillation epidemiology, prevention, and treatment","volume":"12","author":"Morin","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0008","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death. The Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0009","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1185\/030079905X65475","article-title":"Economic burden and co-morbidities of atrial fibrillation in a privately insured population","volume":"21","author":"Wu","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0010","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0011","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0012","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the ACC\/AHA Task Force on Clinical Practice Guidelines and the HRS in Collaboration with the STC","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ajhp\/zxy032","article-title":"Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin","volume":"76","author":"Datar","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0014","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","article-title":"Initiation of warfarin in patient with atrial fibrillation: early effects on ischaemic strokes","volume":"35","author":"Azoulay","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/ph14040290","article-title":"Comparison of direct oral anticoagulant use for the treatment of non-valvular atrial fibrillation in pivotal clinical trials vs. the real-world setting: a population-based study from southern Italy","volume":"14","author":"Ingrasciotta","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0016","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/europace\/euw416","article-title":"Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study","volume":"20","author":"Forslund","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0017","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1161\/STROKEAHA.119.026054","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation. Meta-analysis of randomized trials and real-world studies","volume":"50","author":"Xue","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0018","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.chest.2019.11.025","article-title":"Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly Asian patients with atrial fibrillation: a nationwide cohort study","volume":"157","author":"Chao","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0019","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000682","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation","volume":"4","author":"Friberg","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2018.05.022","article-title":"Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation","volume":"167","author":"Sj\u00e4lander","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0022","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/pds.4194","article-title":"Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry","volume":"26","author":"Lehto","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0023","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control. A systematic review and metaregression","volume":"129","author":"Walraven","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0025","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.clinthera.2014.07.016","article-title":"Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries","volume":"36","author":"Cott\u00e9","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0026","first-page":"159","article-title":"Factors influencing vitamin K antagonist therapy","volume":"23","author":"Brudasca","year":"2015","journal-title":"RJ Lab Med"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0027","first-page":"409","article-title":"Persistence with statin therapy in Hungary","volume":"9","author":"Kiss","year":"2013","journal-title":"Med Sci"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1556\/650.2020.31727","article-title":"Real-world adherence to oral anticoagulants in atrial fibrillation","volume":"161","author":"Simonyi","year":"2020","journal-title":"Orv Hetil"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0029","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/jcm9061969","article-title":"Persistence with anticoagulation for atrial fibrillation: report from the GLORIA-AF Phase III 1-year follow-up. 2020","volume":"9","author":"Kozie\u0142","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00392-014-0742-y","article-title":"Adherence to warfarin treatment among patients with atrial fibrillation","volume":"103","author":"Skeppholm","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0031","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"G\u00f3mez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0032","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/STROKEAHA.116.015535","article-title":"Ischemic stroke in nonvalvular atrial fibrillation at warfarin initiation. Assessment via a large insurance database","volume":"48","author":"Tepper","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0033","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0034","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/eurheartj\/ehu042","article-title":"Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?","volume":"35","author":"Diener","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5853\/jos.2015.17.2.216","article-title":"Paradoxical procoagulant effect of early doses of warfarin: possible role of non-vitamin K oral anticoagulant in patients with atrial fibrillation-related stroke","volume":"17","author":"Kim","year":"2015","journal-title":"J Stroke"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1345\/aph.1A198","article-title":"Relationship between patients' warfarin knowledge and anticoagulation control","volume":"37","author":"Tang","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0037","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0038","first-page":"385","article-title":"Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms","volume":"111","author":"Cove","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0039","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/qjmed\/hcu054","article-title":"Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis","volume":"107","author":"Wagstaff","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jacc.2018.05.015","article-title":"Sex implications in the response to anticoagulant therapy in atrial fibrillation","volume":"72","author":"Renda","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.03.008_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jacc.2018.04.066","article-title":"Sex-based differences in outcomes of oral anticoagulation in patients with atrial fibrillation","volume":"72","author":"Law","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182300108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182300108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:26Z","timestamp":1758963506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182300108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S014929182300108X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}